WOONSOCKET, R.I. — On November 4, 2026, at 6:31 a.m. Eastern Time, CVS Health Corporation (the “Company”) issued a press release announcing its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to the Company and its shareholders for U.S. federal income tax purposes. Alongside the historic structural announcement, CVS reported third-quarter 2026 financial results where total revenues increased to $108.4 billion, up 5.4% year-over-year, and adjusted diluted earnings per share (EPS) climbed to $2.09, comfortably topping consensus forecasts.
Key Takeaways
- Dismantling Vertical Integration: Following a comprehensive strategic review by its Board of Directors, CVS Health plans to complete a tax-free separation in the first half of 2028, dividing into a healthcare solutions company (retaining Aetna and Caremark) and a nationwide retail pharmacy company.
- Earnings Beat and Margin Recovery: Third-quarter GAAP diluted EPS reached $1.68 while adjusted EPS rose 30.6% to $2.09, driven by an adjusted operating income jump at Aetna as medical loss ratios moderated.
- Full-Year Guidance Lifted: CVS raised its full-year 2026 adjusted EPS outlook to at least $8.20 (up from a prior range of $7.90 to $8.10) and projected full-year consolidated revenues of at least $420.0 billion.
The Separation Plan: Creating Two Healthcare Leaders
The proposed separation represents one of the largest corporate breakups in modern healthcare history, unwinding the vertical integration model that CVS championed over the past two decades. Under the plan outlined in Exhibit 99.1 of Form 8-K, the business will bifurcate into two distinct entities:
- The Healthcare Solutions Company: This entity will house health benefits giant Aetna, pharmacy benefit manager CVS Caremark, CVS Specialty, primary care provider Oak Street Health, and home-assessment unit Signify Health. In the interim, this company will retain the CVS Health corporate identity and continue to be led by David Joyner as Chairman and Chief Executive Officer.
- CVS Pharmacy: The retail company will encompass approximately 9,000 CVS retail pharmacies, mail-order pharmacy services, MinuteClinic walk-in clinics (including virtual care), and the Health100 digital technology platform. Prem Shah will lead the independent retail company as Chief Executive Officer.
Unlike earlier speculative reports suggesting an outright divestiture of Aetna, the board opted to keep health insurance (Aetna) and pharmacy benefit management (Caremark) paired together. The corporate split is structured as a tax-free corporate spinoff, a structure readers can explore in depth in our guide to spinoffs vs. split-offs and carve-outs as well as the tax framework governing Section 355 tax-free spinoffs. Both resulting companies are expected to maintain solid investment-grade credit profiles, self-funding free cash flow, and independent capital return programs including regular dividends.
Q3 2026 Segment Breakdown and Operating Results
For the three months ended September 30, 2026, consolidated total revenues expanded to $108,399 million ($108.4 billion) from $102,871 million in the third quarter of 2025. GAAP net income reached $2,171 million ($1.68 per diluted share), reversing a net loss of $(3,990) million ($(3.13) per share) in the prior-year quarter that had been depressed by a $5.7 billion non-cash goodwill impairment charge.
| Segment (in millions) | Q3 2026 Revenue | Q3 2025 Revenue | Q3 2026 Adj. Op. Income | Q3 2025 Adj. Op. Income |
|---|---|---|---|---|
| Health Care Benefits (Aetna) | $36,855 | $35,993 | $912 | $314 |
| Health Services (Caremark & Care Delivery) | $53,964 | $49,266 | $2,106 | $2,050 |
| Pharmacy & Consumer Wellness (Retail) | $35,498 | $36,214 | $1,635 | $1,478 |
| Corporate / Other & Eliminations | $(17,918) | $(18,602) | $(459) | $(383) |
| Consolidated Totals | $108,399 | $102,871 | $4,194 | $3,459 |
Underwriting Recovery at Aetna
The standout catalyst in CVS Health’s third-quarter report was the turnaround within the Health Care Benefits segment. Over the preceding six quarters, elevated utilization across Medicare Advantage plans pressured industry margins, a trend observed across peers such as UnitedHealth Group. In the third quarter of 2026, Aetna generated $912 million in adjusted operating income, nearly tripling the $314 million recorded in Q3 2025.
The segment’s Medical Benefit Ratio (MBR)—which measures medical claims paid as a percentage of premium revenue—improved by 150 basis points to 91.3%, down from 92.8% in the prior-year period. Total medical membership stood at 26.1 million members as of September 30, 2026, compared to 26.7 million a year earlier, reflecting pricing discipline and deliberate benefit recalibration to restore underwriting profitability.
Health Services and Retail Pharmacy Trends
In the Health Services segment, revenues climbed 9.5% year-over-year to $53,964 million, with adjusted operating income edging higher to $2,106 million. Pharmacy claims processed increased to 481.7 million on a 30-day equivalent basis, driven by net new client wins and growth in specialty pharmacy distribution.
Meanwhile, the Pharmacy & Consumer Wellness retail business generated adjusted operating income of $1,635 million on revenues of $35,498 million. Prescriptions filled rose to 470.0 million on a 30-day equivalent basis, up from 461.4 million in Q3 2025. Stronger pharmacy prescription volume and continued operational efficiency initiatives offset softer front-store retail consumer traffic, supporting segment profitability ahead of the planned 2028 operational separation.
Raised 2026 Outlook and Cash Flow Strength
Reflecting third-quarter outperformance, management raised its full-year 2026 financial guidance across key measures:
- Adjusted Diluted EPS: Increased to at least $8.20, up from the previous forecast range of $7.90 to $8.10.
- GAAP Diluted EPS: Increased to at least $6.98, compared to the previous guidance range of $6.84 to $7.04.
- Cash Flow from Operations: Projected at at least $15.5 billion, raised substantially from the prior minimum expectation of at least $11.5 billion. Through the first nine months of 2026, year-to-date operating cash flow totaled $15.3 billion.
- Consolidated Revenues: Anticipated to reach at least $420.0 billion for the full fiscal year.
Key Risks and Catalysts to Watch
While the third-quarter rebound provided immediate operating relief, the path to a 2028 separation involves complex operational, regulatory, and financial hurdles:
- Tax-Free Qualification: The proposed spinoff must satisfy Internal Revenue Code Section 355 requirements, including business continuity and active trade or business tests, alongside obtaining customary tax opinions or IRS private letter rulings.
- PBM Regulatory Scrutiny: CVS Caremark remains subject to ongoing legislative and regulatory examinations regarding pharmacy benefit manager transparency, spread pricing, and rebate structures at both federal and state levels.
- Capital Structure Allocation: As the transaction approaches, debt allocation between the healthcare solutions entity and retail drugstore entity will be critical to ensuring both companies retain investment-grade ratings.
Investors will monitor management’s execution across the 2027 Medicare Advantage annual enrollment cycle and further updates regarding separation timelines during future quarterly updates.
Sources & Further Reading
- SEC Form 8-K (Item 7.01) — CVS Health Separation Announcement, filed November 4, 2026.
- SEC Form 8-K Exhibit 99.1 — CVS Health Separation Press Release, filed November 4, 2026.
- SEC Form 8-K Exhibit 99.1 — CVS Health Q3 2026 Earnings Release, filed November 4, 2026.
- Spinoffs vs. Split-Offs vs. Carve-Outs: Corporate Divestitures, ECMSource.
- How Stock Spinoffs Work: Section 355 Tax-Free Explained, ECMSource.
Disclosure: This article is for informational purposes only and is not investment advice.